TIAP portfolio company Notch Therapeutics has announced one of the largest Series A financing rounds in the history of Canadian biotech. We are proud to say that we were there from the start in 2017 when TIAP received the technology disclosure from Dr. Zuniga-Pflucker via our Member, Sunnybrook Health Sciences Centre, and then again when we teamed up with CCRM and Dr. Peter Zandstra of University of Toronto, another one of our Members. TIAP was an early seed investor and acknowledges ...
December 8, 2020
TIAP announces co-funding of transformative projects with Amgen to support new venture development
Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids).
The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations ...
TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio.
TIAP was one of the earliest investors and partners with Forbius in 2011/12. This is a big win for Forbius CEO Dr. Tikhomirov and the Canadian research and innovation community. Forbius (formerly Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic ...
TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.
The project was initiated in partnership with a group of scientists from Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins. These proteins ...
– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials –
– Series A Financing led by the Perceptive Xontogeny Venture Fund –
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”).
The proceeds from the financing will fund Phase 1 and ...
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor.
Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ...
Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships.
The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) ...
TIAP and DAYLI Partners, a leading biotech venture caital firm in South Korea, are collaborating on the creation of a new venture capital fund focused on biotech and health sciences in Canada. The joint investment team will identify & invest in seed stage companies primarily in Ontario with a portion of the fund allocated to Korean companies with high potential to expand to Ontario. Read more here: http://bit.ly/35FH40K
In their September 11, 2019 online edition as part of their "Innovation this Week" newsletter, Re$earch Money talked about TIAP's partnership agreement with Amgen:
"A few days after celebrating its 10th anniversary and changing its name to Toronto Innovation Acceleration Partners (TIAP), the commercialization organization formerly known as MaRS Innovation announced a new collaboration with the biotechnology company Amgen. The aim of the collaboration is to identify and jointly fund disruptive technologies derived from discovery research conducted in Toronto and managed by ...
Toronto, Ontario, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise in the early-stage health science field, is pleased to announce the establishment of a collaboration with Amgen, a global leader in the biotechnology industry.
Under the terms of the agreement, Amgen and TIAP will jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations will collaborate in a proactive ...